Your session is about to expire
← Back to Search
Study Summary
This trial is a Phase 1/2, multicenter, open-label study of LY3884961, which is being evaluated for safety and tolerability in adults with peripheral manifestations of GD. Up to 3 dose levels of LY3884961 will be assessed in 3 dose-finding cohorts of 3 patients, and then up to 6 patients may be enrolled into an expansion cohort. For each enrolled patient, the study will last approximately 5 years, including up to a 45-day screening period. During the first 18 months after dosing, subjects will be evaluated for the effects of LY3884961 on safety, tolerability, immun
- Gaucher Disease
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is an individual such as myself eligible for participation in this trial?
"To be eligible for the clinical trial, applicants must have Gaucher Disease and between 18-50 years of age. There is capacity to include around 15 patients in the study."
Is registration for this experiment currently taking place?
"According to the clinicaltrials.gov page, this trial is not actively looking for participants at the moment, despite originally being posted on August 1st 2022 and lastly updated a month later. However, there are 15 other studies that are currently open for recruitment."
Are aged participants being accepted into this trial?
"As per the stated guidelines, any individual between 18 and 50 years old can be considered for enrollment in this investigation."
Share this study with friends
Copy Link
Messenger